Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
selective HDAC6 degrader
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "selective HDAC6 degrader" in MCE Product Catalog:
J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1 .
Cat. No.: HY-173266A
Research Areas:
TO-1187 TFA is a selective HDAC6 PROTAC degrader (DC50: 5.81 nM). TO-1187 TFA promotes the ubiquitination and degradation of HDAC6 and can be used in the study of hematological malignancies and solid tumors .
Cat. No.: HY-174444A
PROTAC HDAC degrader-2 TFA is a selective class IIb dual histone deacetylase (HDAC6 and HDAC10) PROTAC degrader, with DC50 values of 13 nM and 29 nM against HDAC6 and HDAC10, respectively. It does not degrade class I (HDAC1/8) and class IIa (HDAC4/7) histone deacetylases .
Cat. No.: HY-171140
Target:
Research Areas:
PROTAC HDAC6 degrader 3 is a selective HDAC6 PROTAC degrader with an IC50 of 0.686 μM and shows high selectivity for HDAC6 over HDAC1-4. PROTAC HDAC6 degrader 3 recruits cereblon (CRBN) to trigger HDAC6 ubiquitination and subsequent proteasomal degradation. PROTAC HDAC6 degrader 3 selectively elevates acetylated α-tubulin levels in cancer cells, and does not induce histone H3 hyperacetylation or obvious loss of cell viability. PROTAC HDAC6 degrader 3 is applicable for research on multiple myeloma .
Cat. No.: HY-171139
Target:
Research Areas:
PROTAC HDAC6 degrader 2 is a non‑hydroxamate selective HDAC6 PROTAC degrader with an IC50 of 0.643 μM and shows high selectivity for HDAC6 over HDAC1-4. PROTAC HDAC6 degrader 2 recruits VHL E3 ubiquitin ligase to trigger HDAC6 ubiquitination and subsequent proteasomal degradation. PROTAC HDAC6 degrader 2 selectively elevates acetylated α-tubulin levels in cancer cells, and does not induce histone H3 hyperacetylation or obvious loss of cell viability. PROTAC HDAC6 degrader 2 is applicable for research on multiple myeloma .
Cat. No.: HY-152133
CAS No.: 2785404-76-2
PROTAC HDAC6 degrader is a potent and selective PROTAC HDAC6 degrader with a DC50 of 3.5 nM. PROTAC HDAC6 degrader shows promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines .
Cat. No.: HY-177758
PROTAC HDAC6 degrader 8 is a potent and selective HDAC6 PROTAC degrader with a DC50 of 1.94 nM. PROTAC HDAC6 degrader 8 induces HDAC6 degradation in cancer cells with a hook effect, and exerts no impact on other HDAC subtypes, IKZF1, IKZF3 or GSPT1. PROTAC HDAC6 degrader 8 can be used in studies related to multiple myeloma .
Cat. No.: HY-173266
Research Areas:
TO-1187 is a selective HDAC6 PROTAC degrader with a DC50 value of 5.81 nM. TO-1187 degrades HDAC6 via the ubiquitin-proteasome pathway. TO-1187 can be used in the research of multiple myeloma, neuroblastoma, and cervical cancer .
Cat. No.: HY-174444
PROTAC HDAC degrader-2 is a selective class IIb dual histone deacetylase (HDAC6 and HDAC10) PROTAC degrader, with DC50 values of 13 nM and 29 nM against HDAC6 and HDAC10, respectively. It does not degrade class I (HDAC1/8) and class IIa (HDAC4/7) histone deacetylases .
Cat. No.: HY-174401
Target:
Research Areas:
PROTAC HDAC6 degrader 5 is a selective HDAC6 PROTAC degrader with an IC50 of 43 nM. PROTAC HDAC6 degrader 5 induces proteasome-dependent degradation of HDAC6 by bridging HDAC6 and CRBN to form a ternary complex. PROTAC HDAC6 degrader 5 is applicable to research related to pulmonary fibrosis .
Cat. No.: HY-179421
CAS No.: 3133307-16-8
Research Areas:
PROTAC HDAC6 degrader 7 is an orally active, highly efficient, and selective PROTAC degrader targeting histone deacetylase 6 (HDAC6) (IC50 = 118 nM). PROTAC HDAC6 degrader 7 can eliminate both the catalytic and zinc-finger ubiquitin-binding domain. PROTAC HDAC6 degrader 7 inhibits NLRP3 inflammasome assembly and activation, as well as blocks NF-κB signaling, thereby reducing the transcription and release of key inflammatory factors. PROTAC HDAC6 degrader 7 can reduce the mRNA levels of NLRP3, pro-IL-1β, TNF-α, and IL-6. PROTAC HDAC6 degrader 7 can be used for the study of inflammatory bowel disease (IBD) .
Cat. No.: HY-168175
PROTAC HDAC8 Degrader-2 is a HDAC6/8 PROTAC degrader, with IC50 values of 0.042 μM and 0.147 μM against human HDAC8 and HDAC6, respectively, and exhibits selectivity over other class I HDAC isozymes. PROTAC HDAC8 Degrader-2 induces apoptosis (apoptosis) in leukemia cells, shows no obvious cytotoxicity to normal cells, and has favorable chemical stability. PROTAC HDAC8 Degrader-2 can be used in research related to acute myeloid leukemia .
Cat. No.: HY-159172
CAS No.: 2988762-46-3
HDAC3-IN-4 is a selective and orally active HDAC3 inhibitor with an IC50 of 89 nM. HDAC3-IN-4 induces the degradation of PD-L1 by regulating cathepsin B (CTSB) in the lysosomes, with a DC50 of 5.7 μM. HDAC3-IN-4 shows better selectivity for HDAC3 over HDAC1, HDAC6, HDAC7, and HDAC8 .
Cat. No.: HY-172359
PROTAC HDAC6 degrader 4 is a potent and selective HDAC6 PROTAC degrader with an IC50 of 0.295 μM. PROTAC HDAC6 degrader 4 bridges HDAC6 and the CRBN E3 ubiquitin ligase to form a ternary complex, thereby inducing the specific degradation of HDAC6 via the ubiquitin-proteasome system . PROTAC HDAC6 degrader 4 can be used in studies related to multiple myeloma .
Cat. No.: HY-189306
Research Areas:
PROTAC HDAC6 degrader-13 is a selective CRBN-recruiting HDAC6 PROTAC degrader. PROTAC HDAC6 degrader-13 does not affect class I HDACs. PROTAC HDAC6 degrader-13 inhibits TLR-NLRP3 inflammatory signaling. PROTAC HDAC6 degrader-13 is useful for research on acute myeloid leukemia .
Cat. No.: HY-184389
Target:
Research Areas:
PROTAC HDAC6 degrader 10 is a highly efficient, safe and selective HDAC6 PROTAC degrader with a pIC50 of 8.75 and a pDC50 of 9.2 in BEAS-2B cells. PROTAC HDAC6 degrader 10 recruits cereblon to form a ternary complex with HDAC6, thereby achieving the degradation of HDAC6. PROTAC HDAC6 degrader 10 significantly induces hyperacetylation of α-tubulin without affecting the acetylation of H3, and achieves sustained HDAC6 knockdown in mouse lung tissues. PROTAC HDAC6 degrader 10 exhibits high bioavailability after subcutaneous administration in mice. PROTAC HDAC6 degrader 10 enables the study of HDAC6 pharmacology via chemical knockdown of HDAC6 in vitro and in vivo, and can be used for research on pulmonary diseases .
Cat. No.: HY-187387
CAS No.: 3092711-76-4
Target:
Research Areas:
PROTAC HDAC6/ERα degrader 1 is a dual-target PROTAC that targets HDAC6/ERα, with DC50 values of 1.21 μM (HDAC6), 0.28 μM (ERα) in MCF-7 cells and 0.67 μM (HDAC6), 0.14 μM (ERα) in LCC2 cells, respectively. PROTAC HDAC6/ERα degrader 1 selectively degrades ERα and HDAC6 via the proteasomal pathway, inhibits the transcriptional activation of ERα and blocks the estrogen signaling pathway. PROTAC HDAC6/ERα degrader 1 inhibits the function of HDAC6, attenuates hormone responses, and disrupts autophagy-lysosome function. PROTAC HDAC6/ERα degrader 1 induces cell cycle arrest, apoptosis and ferroptosis, and exhibits antiproliferative activity in breast cancer cells. PROTAC HDAC6/ERα degrader 1 can be used for breast cancer research .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
